We analyzed the association between EP300 mutations and drug sensitivity (IC50 values) of cancer cell lines to 192 antitumor compounds from the GDSC project.7 Interestingly, EP300-mutated cell lines had significantly lower IC50 values than EP300-wild-type cell lines for 44 compounds (one-tailed Mann–Whitney U test, p < 0.05) (Figure 5). The gene discussed is EP300; the disease is cancer.